Placebo + Reduced-calorie diet + Tirzepatide for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 2 Feb 2026: Trial started, NCT07481747
  2. 19 Mar 2026: Trial registered, NCT07481747

The trials

NCT07481747: Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)

State
Under way
Phase
Phase 3
People
2,539 planned
Started
2 Feb 2026
Primary completion
14 Feb 2027
Arms
Arm 1: Tirzepatide 5 mg once weekly + lifestyle intervention, Arm 2: Tirzepatide 10 mg once weekly + lifestyle intervention, Arm 3: Tirzepatide 15 mg once weekly + lifestyle intervention, Arm 4: Placebo once weekly + lifestyle intervention
Results
None posted
  1. 2 Feb 2026: Trial started
  2. 19 Mar 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.